Antiplatelet therapy deescalation has been suggested as an alternative to standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding risk patients with acute coronary syndromes undergoing percutaneous coronary intervention to mitigate the increased risk of bleeding. Whether this strategy preserves the ischemic and survival benefits of potent DAPT is uncertain.
Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis / Palmerini T.; Bruno A.G.; Gasparini M.; Rizzello G.; Kim H.-S.; Kang J.; Park K.-W.; Hahn J.-Y.; Song Y.B.; Gwon H.-C.; Choo E.H.; Park M.-W.; Kim C.J.; Chang K.; Cuisset T.; Taglieri N.; Kim B.-K.; Jang Y.; Nardi E.; Saia F.; Orzalkiewicz M.; Chietera F.; Ghetti G.; Galie N.; Stone G.W.. - In: CIRCULATION. CARDIOVASCULAR INTERVENTIONS. - ISSN 1941-7632. - STAMPA. - 15:11(2022), pp. 906-914. [10.1161/CIRCINTERVENTIONS.122.012245]
Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis
Palmerini T.;Bruno A. G.;Taglieri N.;Nardi E.;Saia F.;Orzalkiewicz M.;Chietera F.;Ghetti G.;Galie N.;
2022
Abstract
Antiplatelet therapy deescalation has been suggested as an alternative to standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding risk patients with acute coronary syndromes undergoing percutaneous coronary intervention to mitigate the increased risk of bleeding. Whether this strategy preserves the ischemic and survival benefits of potent DAPT is uncertain.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
